Literature DB >> 8560197

Oral tolerization leads to active suppression and bystander tolerance in adult rats while anergy dominates in young rats.

B S Lundin1, U I Dahlgren, L A Hanson, E Telemo.   

Abstract

Oral tolerance was induced in 4-week-old (young) and 12-week-old (adult) rats by feeding ovalbumin (OvA)-containing pellets during 4 weeks. Seven weeks after removal of the OvA-pellets the rats were immunized with a mixture of OvA and human serum albumin (HSA) in Freund's complete adjuvant (FCA), and the following immune response was monitored. Both the young and adult groups of OvA-fed rats had significantly suppressed OvA-specific delayed-type hypersensitivity (DTH) responses and T-cell proliferation, reflecting a long-lasting T-cell tolerance to OvA both in vivo and in vitro. Furthermore, spleen cells from rats tolerized as adults were able to suppress the proliferation of primed T-cells from normal immunized rats, demonstrating the presence of antigen-specific suppressive cells. Accordingly, the adult rats showed bystander suppression of the response to HSA with respect to DTH-reaction, specific proliferation, and reduced enlargement of the draining lymph nodes after immunization. There was no evidence of active suppression in vitro or bystander tolerance in the orally tolerized young group, indicating that anergy rather than active suppression was prevalent in these rats. Furthermore, in the young group there was no suppression of the antibody response since the IgG and IgE anti-OvA antibody levels were indistinguishable from those of the controls. Contrary to the young rats, the adult fed group showed transiently elevated levels of IgG anti-OvA antibodies at 1 week post-immunization, followed by a subsequent significantly suppressed IgG antibody response. In conclusion, the results demonstrate that the induction of anergy or active suppression after antigen feeding can be determined by the age at which the antigen is introduced to the mucosal immune system.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8560197     DOI: 10.1046/j.1365-3083.1996.d01-15.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  7 in total

1.  Active suppression in orally tolerized rats coincides with in situ transforming growth factor-beta (TGF-beta) expression in the draining lymph nodes.

Authors:  B S Lundin; M R Karlsson; L A Svensson; L A Hanson; U I Dahlgren; E Telemo
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

2.  Oral immune regulation using colitis extracted proteins for treatment of Crohn's disease: results of a phase I clinical trial.

Authors:  Eran Israeli; Eran Goldin; Oren Shibolet; Athalia Klein; Nilla Hemed; Dean Engelhardt; Elazar Rabbani; Yaron Ilan
Journal:  World J Gastroenterol       Date:  2005-05-28       Impact factor: 5.742

3.  Immunomodulatory effects of Lactobacillus plantarum colonizing the intestine of gnotobiotic rats.

Authors:  M V Herías; C Hessle; E Telemo; T Midtvedt; L A Hanson; A E Wold
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

4.  Bystander effect in synergy to anergy in oral tolerance of Blomia tropicalis/ovalbumin murine co-immunization model.

Authors:  C R Oliveira; E A F Taniguchi; A E Fusaro; J R Victor; C A Brito; A J S Duarte; M N Sato
Journal:  J Clin Immunol       Date:  2005-03       Impact factor: 8.317

5.  Tolerance and bystander suppression, with involvement of CD25-positive cells, is induced in rats receiving serum from ovalbumin-fed donors.

Authors:  M R Karlsson; H Kahu; L A Hanson; E Telemo; U I Dahlgren
Journal:  Immunology       Date:  2000-07       Impact factor: 7.397

6.  Induction of immunologic tolerance to myelin basic protein prevents central nervous system autoimmunity and improves outcome after stroke.

Authors:  J Michael Gee; Angela Kalil; Matthew Thullbery; Kyra J Becker
Journal:  Stroke       Date:  2008-03-06       Impact factor: 7.914

7.  Bystander suppression of collagen-induced arthritis in mice fed ovalbumin.

Authors:  N Fredrik Bäckström; Ulf I H Dahlgren
Journal:  Arthritis Res Ther       Date:  2004-02-05       Impact factor: 5.156

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.